MediWound Ltd. (MDWD)

18.90 +0.25 (+1.34%) At close: 04:00PM EDT

MediWound Ltd.

42 Hayarkon Street
Yavne 8122745
Israel
972 7 797 14100
https://www.mediwound.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ofer Gonen B.Sc.	Chief Executive Officer	649k	N/A	1973
Ms. Hani Luxenburg	Chief Financial Officer	235k	N/A	1973
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.	Chief Medical Officer	N/A	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Corporate governance

MediWound Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.